• Realbotix's wholly owned subsidiary agreed to an additional USD 500,000 advance from Onconetix to support working capital ahead of their proposed merger.
• The draw raises total advances from USD 2.5 million to USD 3 million under the USD 5 million facility.
• The September 14, 2026, agreement provides an unsecured, non-interest-bearing promissory note guaranteed by Realbotix.
• Closing the merger will automatically cancel the note and discharge all loan obligations without payment.
• Termination of the merger agreement would trigger 12% annual interest on outstanding principal from the termination date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Realbotix Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230730BIZWIRE_USPR_____20261023_BW966631) on October 23, 2026, and is solely responsible for the information contained therein.